###begin article-title 0
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
High Frequency of Copy Number Variations and Sequence Variants at CYP21A2 Locus: Implication for the Genetic Diagnosis of 21-Hydroxylase Deficiency
###end article-title 0
###begin p 1
Conceived and designed the experiments: SP LL. Performed the experiments: SP LL CQ. Analyzed the data: FD SP LL. Wrote the paper: FD SP LL.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 420 428 420 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2,</italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 477 482 <span type="species:ncbi:9606">human</span>
###xml 576 584 <span type="species:ncbi:9606">patients</span>
The systematic study of the human genome indicates that the inter-individual variability is greater than expected and it is not only related to sequence polymorphisms but also to gene copy number variants (CNVs). Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency (21OHD) is the most common autosomal recessive disorder with a carrier frequency of 1:25 to 1:10. The gene that encodes 21-hydroxylase enzyme, CYP21A2, is considered to be one of the most polymorphic human genes. Copy number variations, such as deletions, which are severe mutations common in 21OHD patients, or gene duplications, which have been reported as rare events, have also been described. The correct characterization of 21OHD alleles is important for disease carrier detection and genetic counselling
###end p 3
###begin title 4
Methodology and Findings
###end title 4
###begin p 5
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 216 223 216 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 396 403 396 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 516 523 516 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
CYP21A2 genotyping by sequencing has been performed in a random sample of the Spanish population, where 144 individuals recruited from university students and employees of the hospital were studied. The frequency of CYP21A2 mutated alleles in our sample was 15.3% (77.3% were mild mutations, 9% were severe mutations and 13.6% were novel variants). Gene dosage assessment was also performed when CYP21A2 gene duplication was suspected. This analysis showed that 7% of individuals bore a chromosome with a duplicated CYP21A2 gene, where one of the copies was mutated.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 168 175 168 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
As far as we know, the present study has shown the highest frequency of 21OHD carriers reported by a genotyping analysis. In addition, a high frequency of alleles with CYP21A2 duplications, which could be misinterpreted as 21OHD alleles, was found. Moreover, a high frequency of novel genetic variations with an unknown effect on 21-hydroxylase activity was also found. The high frequency of gene duplications, as well as novel variations, should be considered since they have an important involvement in carrier testing and genetic counseling.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 822 825 822 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Speiser1">[1]</xref>
###xml 826 829 826 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Krone1">[3]</xref>
Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency (21OHD) (OMIM +201910) is the most common autosomal recessive disorder. This enzymatic deficiency impairs synthesis of cortisol and/or aldosterone from cholesterol in the adrenal cortex. The severe deficiency of steroid 21-hydroxylase enzyme (21OH; EC 1.14.99.10) results in the classic form of the disease, which is divided firstly, into the salt-wasting form, where neither cortisol nor aldosterone is synthesized; and secondly, into the simple virilizing form, where a residual activity of 21OH allows aldosterone synthesis. The moderate deficiency of 21OH results in the non classic form of the disease (NC21OHD), which is characterized by precocious pseudopuberty, acne, hirsutism and oligomenorrhea, although phenotypical expression is highly variable [1]-[3].
###end p 9
###begin p 10
###xml 105 108 105 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-BaumgartnerParzer1">[4]</xref>
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-vanderKamp1">[8]</xref>
###xml 276 279 276 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-New1">[2]</xref>
###xml 281 284 281 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Zerah1">[9]</xref>
###xml 639 642 639 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-BaumgartnerParzer1">[4]</xref>
###xml 644 648 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Fitness1">[10]</xref>
###xml 723 731 723 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2,</italic>
###xml 813 821 813 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P</italic>
###xml 927 931 927 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-BaradaranHeravi1">[11]</xref>
###xml 932 936 932 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Stikkelbroeck1">[20]</xref>
###xml 661 669 <span type="species:ncbi:9606">patients</span>
The incidence of the classic form of the disease is 1:23000-1:10000 depending on the populations studied [4]-[8] and the incidence of the NC21OHD is 1:500-1:100 in most populations. It can be more frequent in other populations like in the Ashkenazi Jews with a 1:27 incidence [2], [9]. The carrier frequency of 21OHD, estimated on the basis of newborn screening, is between 0.011 and 0.020 for severe mutations and 0.08 to 0.18 for mild ones. On the other hand, genotyping analyses done in New Zealanders and Middle Europeans have shown higher frequencies for carriers of severe mutations (0.040-0.055) and lower for mild ones (0.02-0.04) [4], [10]. Most 21OHD patients are carriers of deletions of the gene encoding 21OH, CYP21A2, or of any of the 9 most frequent point mutations derived from the non-functional CYP21A1P pseudogene. The rest are due to rare genetic variants, descriptions of which are continuously increasing [11]-[20].
###end p 10
###begin p 11
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 42 50 42 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P</italic>
###xml 261 264 261 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Speiser1">[1]</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-White1">[21]</xref>
###xml 335 349 335 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RP1, C4, TNXB,</italic>
###xml 382 385 382 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RP2</italic>
###xml 390 395 390 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA.</italic>
###xml 437 452 437 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RP-C4-CYP21-TNX</italic>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Yang1">[22]</xref>
###xml 532 540 532 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002138-g001">Figure 1</xref>
###xml 600 608 600 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P</italic>
###xml 643 650 643 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 720 724 720 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Yang1">[22]</xref>
###xml 725 729 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-HaglundStengler1">[27]</xref>
The CYP21A2 gene is 98% homologous to the CYP21A1P pseudogene in its coding sequence and 96% in introns. Both lie in the Major Histocompatibility Complex at chromosome 6p21.3, which is a complex organization of genes with variation in gene copy number and size [1], [21]. They constitute a genetic unit together with neighboring genes RP1, C4, TNXB, and their truncated pseudogenes RP2 and TNXA. This genetic unit is termed RCCX module (RP-C4-CYP21-TNX) and constitutes a highly variable stretch of DNA of approximately 30 kb [22] (Figure 1). Most chromosomes bear two of these modules, one with the CYP21A1P pseudogene and the other with the CYP21A2 gene. Monomodular and trimodular haplotypes have also been described [22]-[27].
###end p 11
###begin title 12
Organization of RCCX module and Copy Number Variations at chromosome 6p21.
###end title 12
###begin p 13
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB.</italic>
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA</italic>
Black horizontal arrows denote gene orientation. A. Specific primers used for the amplification of CYP21A2 next to TNXB. B. Specific primers used for the amplification of CYP21A2 next to TNXA. Primer binding sites for each primer are indicated by grey horizontal arrows.
###end p 13
###begin p 14
###xml 32 39 32 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 215 222 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 327 334 327 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
The high genetic variability at CYP21A2 locus makes the characterization of 21OHD alleles difficult, and, hence, complicates disease carrier detection and genetic counseling. In this paper, an in-depth study of the CYP21A2 gene in a group of 144 individuals is described. We found an unexpectedly high 21OHD carrier frequency, CYP21A2 gene duplications and CYP21A2 novel genetic variations. The results of the current work should be considered for 21OHD genetic diagnosis and counseling.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
###xml 37 44 37 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
Copy Number Variations: frequency of CYP21A2 gene duplications
###end title 16
###begin p 17
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 168 175 168 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 558 565 558 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 681 688 681 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 701 705 701 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB</italic>
###xml 744 751 744 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 764 768 764 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA</italic>
The CYP21A2 gene dosage assessment by Real-Time PCR and by the specific amplification of each duplicated gene showed that 8 out of the 144 individuals were carriers of CYP21A2 gene duplication with one of the copies p.Gln318X mutated (UniProtKB ID P08686). In all the cases, the mutation was in linkage disequilibrium with two uncommon genetic variants, a G>A change in intron 2 at position -79 and a C>T change at nucleotide 13 in the 3' UTR region (c.293-79G>A and c.*13C>T, respectively, GenBank Ref. ID NM000500.5). The PCRs for the amplification of the CYP21A2 duplicated genes confirmed the duplication. The specific sequencing of each gene showed the severe mutation on the CYP21A2 next to the TNXB gene, and the presence of a wild-type CYP21A2 next to the TNXA pseudogene.
###end p 17
###begin p 18
###xml 94 110 94 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P/CYP21A2</italic>
###xml 207 214 207 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 435 442 435 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 534 550 534 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P/CYP21A2</italic>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA</italic>
###xml 617 624 617 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 637 641 637 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB</italic>
Two other gene duplications were found by Real-Time PCR in two chromosomes bearing a chimeric CYP21A1P/CYP21A2. The duplications had been suspected by the presence of heterozygosity in the PCR products of a CYP21A2 fragment despite the fact that both individuals were carriers of p.Ile236Asn, p.Val237Glu, and p.Met239Lys mutations, which prevented the specific primer from its binding. The PCRs for the specific amplification of each CYP21A2 duplicated gene confirmed the duplication. The sequencing of each gene showed the chimeric CYP21A1P/CYP21A2 gene next to the TNXA pseudogene, and the presence of a wild-type CYP21A2 next to the TNXB gene.
###end p 18
###begin p 19
###xml 200 207 200 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
The total number of duplications found in our sample results in a duplication allele frequency of 0.035, which meant a 7% frequency of carriers. Most of them bore the p.Gln318X mutation in one of the CYP21A2 genes.
###end p 19
###begin title 20
Sequence Variations: frequency of putative disease-causing alleles
###end title 20
###begin p 21
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 50 57 50 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002138-t001">Table 1</xref>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 403 410 403 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0002138-t001">Table 1</xref>
A total of 22 CYP21A2 mutated alleles were found (Table 1), which indicated that 16% of individuals were mutation carriers. No significant differences were found between males and females. Seventeen of these CYP21A2 genetic variants were known to maintain a residual 21-hydroxylase enzyme (21OH) activity, 2 completely impaired it, and 3 were novel variants with an unknown effect on the 21OH activity (Table 1).
###end p 21
###begin title 22
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2 g</italic>
CYP21A2 genetic variations found in a random sample of 144 Spaniards.
###end title 22
###begin p 23
Single Nucleotide Polymorphisms and the insertion of CTG encoding Leu10 are not reported in this table.
###end p 23
###begin p 24
GenBank Ref. ID NM_000500.5.
###end p 24
###begin p 25
UniProtKB ID P08686.
###end p 25
###begin p 26
21OH: 21-hydroxylase.
###end p 26
###begin p 27
Data obtained from White et al. 2000.
###end p 27
###begin p 28
###xml 21 37 21 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P/CYP21A2</italic>
Conversion: Chimeric CYP21A1P/CYP21A2.
###end p 28
###begin p 29
p.[Pro30Leu;Gly110del8nt].
###end p 29
###begin p 30
p.[Ile172Asn;Asp183Glu;Ile236Asn;Val237Glu;Met239Lys;Val281Leu;Phe306ins1T].
###end p 30
###begin p 31
p.[Asp183Glu;Ile236Asn;Val237Glu;Met239Lys;Val281Leu;Phe306ins1T;Arg356Trp].
###end p 31
###begin title 32
Mild mutations
###end title 32
###begin p 33
The allele frequency for mild mutations was 0.059. The most frequent was p.Val281Leu, which was carried by 11% individuals.
###end p 33
###begin title 34
Severe mutations
###end title 34
###begin p 35
###xml 64 80 64 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P/CYP21A2</italic>
The allele frequency for severe mutations was 0.007. A chimeric CYP21A1P/CYP21A2 gene was carried by an individual and p.Gly291Ser was carried by another.
###end p 35
###begin title 36
Novel genetic variations
###end title 36
###begin p 37
###xml 153 161 153 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002138-g002">Figure 2</xref>
In our sample, 0.010 alleles carried novel genetic variants: p.Trp22Cys, p.Asp184Asn, and p.Thr443Asn. Each of these was found in different individuals (Figure 2). The effect of these mutations on the 21OH activity is unknown.
###end p 37
###begin title 38
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
Electropherograms obtained for the three novel mutations in CYP21A2 gene and the corresponding wild-type alleles.
###end title 38
###begin p 39
1. The base change from G to T at position 69 leads to the substitution of tryptophan 22 by cysteine; 2. The base change from G to A at position 553 replaces aspartic acid 184 by asparagine; 3. The base change from C to A at positition 1996 leads to the substitution of threonine 443 by asparagine. (GenBank Ref. ID NM_000500.5; UniProtKB ID P08686). Wt: wild-type; Mut: mutated.
###end p 39
###begin title 40
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
CYP21A2 gene polymorphisms and haplotypes
###end title 40
###begin p 41
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
In the 288 chromosomes analyzed, a total of 79 different genetic variants were found. They were distributed in the vicinity 5' and 3' UTR of the CYP21A2 gene as well as in introns and exons. Haplotype inference from data obtained for the 20 most polymorphic genetic variations enabled the identification of 75 different haplotypes. Most of them appeared only once, but others were recurrent. These latter were the haplotype associated to the p.Gln318X mutation, which is unique, or the haplotype associated to the p.Val281Leu mutation, which was present in 75% of these mutated alleles (data not shown).
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 141 144 141 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Speiser1">[1]</xref>
###xml 146 150 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-ReyListe1">[28]</xref>
###xml 242 249 242 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 308 311 308 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-BaumgartnerParzer1">[4]</xref>
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Fitness1">[10]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Therrell1">[29]</xref>
###xml 556 563 556 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 620 627 620 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 835 843 835 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2.</italic>
The estimated frequency of 21OHD allele carriers among different populations is 1.8% when inferred from the hormonal neonatal screening data [1], [28], which is designed to detect mostly the classic form of 21OHD. The frequency determined by CYP21A2 genotyping, which also detects NC21OHD, is from 4% to 10% [4], [10]. It has been reported that 14% of classic forms and 84% of non-classic forms are missed on the neonatal screening performed during the first days of life [29]. There are no 21OHD carrier frequency data for the Spanish population based on CYP21A2 genotyping. In this study, the complete analysis of the CYP21A2 gene has been performed in 144 random volunteers. The object of the study was firstly, to determine the frequency of 21OHD carriers and secondly, to characterize rare RCCX modules in alleles with duplicated CYP21A2. Although the sample size was small, our data concord with previously published studies (8); it may have been preferable to have determined the carrier frequency using a larger sample; this, however, was both time-consuming and expensive.
###end p 43
###begin p 44
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Blanchong1">[23]</xref>
###xml 331 339 331 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P</italic>
###xml 371 378 371 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 457 464 457 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 490 498 490 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P</italic>
###xml 609 625 609 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P/CYP21A2</italic>
###xml 649 653 649 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Blanchong1">[23]</xref>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-HaglundStengler1">[27]</xref>
###xml 855 862 855 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 876 880 876 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB</italic>
###xml 912 919 912 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 936 940 936 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA</italic>
###xml 974 978 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Lee1">[30]</xref>
###xml 1018 1025 1018 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 1045 1049 1045 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB</italic>
Copy number variations (CNVs) have been described for the RCCX locus: the presence of two RCCX modules is the standard and the presence of one, three or even four modules are rare arrangements. The trimodular organization accounts for only 14% of the chromosomes in population studies [23] and the majority carry two copies of the CYP21A1P pseudogene and one copy of the CYP21A2 gene. The trimodular haplotype has also been described with two copies of the CYP21A2 gene and one copy of the CYP21A1P pseudogene. This latter haplotype has been described, in some carriers of the p.Gln318X mutation and chimeric CYP21A1P/CYP21A2 genes, as a rare event [23]-[27]. Our series, however, have shown a high frequency of this arrangement, 7% of individuals. The specific amplification and sequencing of each duplicated gene localized the p.Gln318X mutation at the CYP21A2 gene next to TNXB gene and it showed a wild-type CYP21A2 at the 3'UTR of TNXA pseudogene. Thus, PCR approaches [30] based on the specific amplification of CYP21A2 like genes next to TNXB would fail in the detection of the wild-type gene and would misdiagnose these duplicated alleles as pathologic, which they are certainly not.
###end p 44
###begin p 45
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 182 189 182 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 252 259 252 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-BaumgartnerParzer2">[13]</xref>
The duplicated CYP21A2 alleles found bear one inactivated gene due to the severe mutations and a wild-type gene which abolishes the pathological effect of the mutation. Furthermore, CYP21A2 duplications have recently been reported as a risk factor for de novo mutations in the offspring [13]. Hence, an awareness of the presence of these types of gene duplications is important if a misdiagnosis is to be avoided. A possible misdiagnosis could be the erroneous identification of a wild type allele as pathological. This is critical for the molecular diagnosis of 21OHD, as well as for prenatal testing and for genetic counseling.
###end p 45
###begin p 46
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
We found that 15.3% of individuals from our sample were carriers of CYP21A2 mutations including novel variants. As far as we know, this is the highest carrier frequency described so far.
###end p 46
###begin p 47
###xml 361 364 361 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-New1">[2]</xref>
###xml 489 492 489 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-BaumgartnerParzer1">[4]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Fitness1">[10]</xref>
###xml 628 635 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
The percentage of individuals who were carriers of NC21OHD was 12%. The application of Hardy-Weinberg equilibrium to our frequency data, estimated the incidence of the mild form of the disease in 1:225. This value is a more precise estimation than the incidence estimated by clinical diagnosis because the latter may underdiagnose patients with mild phenotypes [2]. The frequency of NC21OHD carrier found by genotyping in unselected Middle Europeans and New Zealanders was lower than ours [4], [10]. This may reflect ethnic differences between the populations studied. Although it should be noted that we sequenced the complete CYP21A2 gene whereas the other genotyping based studies only analyzed the 9-11 most common mutations.
###end p 47
###begin p 48
###xml 254 257 254 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-New1">[2]</xref>
###xml 259 263 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Loidi1">[18]</xref>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
In this investigation, as the Middle Europeans and New Zealanders studies, the p.Val281Leu mutation was the most common mutation among NC21OHD alleles (94% in our sample). This was consistent with the reported mutational spectrum of non-classic patients [2], [18].
###end p 48
###begin p 49
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Fitness1">[10]</xref>
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-White1">[21]</xref>
###xml 339 342 339 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-BaumgartnerParzer1">[4]</xref>
###xml 440 443 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Steigert1">[6]</xref>
###xml 444 447 444 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-vanderKamp1">[8]</xref>
###xml 466 473 466 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 497 513 497 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P/CYP21A2</italic>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Krone4">[31]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Wedell2">[32]</xref>
###xml 639 643 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Loidi1">[18]</xref>
###xml 744 748 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Rumsby1">[33]</xref>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Deneux1">[35]</xref>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
The frequency of carriers of severe mutations found (1.4%) corresponded with the incidence of the classic form observed in ours, as well as other populations. It is also similar to data obtained from genotyping in New Zealanders [10], [21]. Nevertheless, it is much lower than the frequency described for Middle European population (5.5%) [4]. This may reflect a different incidence of classic 21OHD when European populations were compared [6]-[8]. The frequency of CYP21A2 deletions and chimeric CYP21A1P/CYP21A2 genes found was lower than the 15-20% described by other authors [31], [32]. However, it corresponded with our previous work [18] and it is similar to the frequency observed in classic 21OHD patients from Italy, France or England [33]-[35].
###end p 49
###begin p 50
###xml 334 341 334 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 506 514 506 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 482 490 <span type="species:ncbi:9606">patients</span>
Three novel genetic variants were found, (p.Trp22Cys, p.Asp184Asn, and p.Thr443Asn) which account for approximately 1% of chromosomes. Two of them, p.Trp22Cys and p.Thr443Asn, are predicted to damage 21-hydroxylase activity (PolyPhen tool ()). The high frequency of novel genetic variants shows the importance of sequencing the whole CYP21A2 gene before it can be considered as wild-type. In some cases, the effect of novel genetic variants may be deduced from the phenotype of the patients. Nevertheless, in vitro functional studies are needed to ascertain them and, if possible, they should be made before considering a variation as a pathological mutation or as a functional polymorphism.
###end p 50
###begin p 51
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Cargill1">[36]</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
The CYP21A2 analysis in our Spanish random population has confirmed that this gene is one of the most polymorphic human ones, as it has already been described by Cargill and co-workers [36]. We found up to 79 different genetic variations at this locus. Twenty of these genetic variations showed a minor allele frequency higher than 0.01. These polymorphic variations rendered up to 73 different haplotypes (data not shown), most of them occurred only once.
###end p 51
###begin p 52
###xml 150 157 150 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
In conclusion, as far as we know, the present study has shown the highest frequency of 21OHD carriers reported by a genotyping analysis. In addition, CYP21A2 gene duplications with one of the copies mutated have been found to be a common event. Moreover, a high frequency of novel genetic variants with an unknown effect on 21OH activity was found and represents a source of uncertainty in 21OHD genetic diagnosis. The number of novel variants, as well as gene duplications found here, could be as high in other populations and should be considered when the 21OHD genetic diagnosis and genetic counseling is carried out.
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
DNA samples
###end title 54
###begin p 55
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
The CYP21A2 gene was studied in a random sample of 144 individuals (95 females, 49 males) recruited from the university students and employees of the hospital. Information about their parents' and grandparents' geographic origins was provided. All these individuals gave informed consent for the analysis, and the procedures were conducted according to the principles expressed in the Declaration of Helsinki.
###end p 55
###begin title 56
Genetic analysis
###end title 56
###begin p 57
DNA was extracted from peripheral blood leucocytes by standard procedures.
###end p 57
###begin title 58
Sequencing
###end title 58
###begin p 59
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Loidi1">[18]</xref>
The CYP21A2 gene and the closest 5' and 3' UTR were sequenced after being amplified in two overlapping fragments by the polymerase chain reaction method as previously described [18].
###end p 59
###begin title 60
CYP21A2 copy number assessment:
###end title 60
###begin p 61
###xml 8 15 8 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 179 186 179 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 259 263 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Parajes1">[37]</xref>
For the CYP21A2 gene dosage assessment, 100 ng of DNA were used. The analytical procedure was based on a Real-Time PCR method, using specific primers for the amplification of the CYP21A2 gene, and TaqMan(R) (Applied Biosystems) probes as previously described [37].
###end p 61
###begin title 62
Specific amplification of each duplicated CYP21A2 gene
###end title 62
###begin p 63
Different DNAs previously characterized by southern blot and the Real-Time PCR method were used as controls for the following PCRs
###end p 63
###begin p 64
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB</italic>
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002138-Lee1">[30]</xref>
###xml 272 276 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB</italic>
###xml 335 342 335 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 347 355 347 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P</italic>
###xml 391 398 391 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 460 467 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
A.- For the amplification of the CYP21A2 at the 3' UTR of TNXB, the strategy described by Lee HH and co-workers was followed [30]. This is based on the amplification of an 8515 bp fragment by the use of a reverse primer (Tena32F), which anneals specifically to exon 32 of TNXB. The forward primer (CYP779F) is common for the 5' UTR of CYP21A2 and CYP21A1P. The samples with a single copy of CYP21A2 on a chromosome, as well as those samples with two copies of CYP21A2 on the same chromosome, have to be positive for this PCR.
###end p 64
###begin p 65
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA</italic>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA</italic>
###xml 325 328 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RP2</italic>
###xml 439 441 439 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C4</italic>
###xml 473 481 473 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002138-g001">Figure 1</xref>
###xml 514 521 514 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 597 604 597 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 665 673 665 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002138.s001">Table S1</xref>
B.- For the amplification of the CYP21A2 gene at the 3' UTR of TNXA, we designed three different PCRs using a forward primer (P3S) that anneals specifically to exon 3 of CYP21A2 and: B1, a reverse primer (1R), which anneals to TNXA producing a fragment of 4611 bp. B2, with reverse primer (2R), which specifically anneals to RP2 and forward primer (P3S) resulting in a 7042 bp fragment and B3, with a reverse primer (3R), which anneals to C4 producing a 7475 bp fragment. (Figure 1) The samples with a single copy CYP21A2 on a chromosome have to be negative for these PCRs, while samples with two CYP21A2 copies on a chromosome have to be positive for these PCRs. (Table S1. PCR conditions under request).
###end p 65
###begin p 66
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
###xml 176 192 176 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A1P/CYP21A2</italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXB</italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNXA.</italic>
The duplicated CYP21A2 alleles found were subjected to these PCRs and the products obtained were sequenced in order to know whether the p.Gln318X mutated copy and the chimeric CYP21A1P/CYP21A2 genes were next to TNXB or to TNXA.
###end p 66
###begin title 67
Haplotype construction
###end title 67
###begin p 68
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP21A2</italic>
The Bayesian statistical method implemented in the program PHASE v2.1.1 was used for the haplotype construction. Only DNA variations, pathologic or not, with a minor allele frequency higher than 0.01 were considered. This selection criterion resulted in 20 genetic variations distributed all over the CYP21A2 gene, as well as the closest 5' and 3' UTR. Eighteen of these variations were biallelic markers, and two were triallelic markers: rs6451 and rs6467. It was also included the polymorphic insertion of an extra leucine in exon 1, and the deletion of a G at position -106 of intron 2 (rs41315224).
###end p 68
###begin title 69
Supporting Information
###end title 69
###begin p 70
Sequences of primers.
###end p 70
###begin p 71
(0.03 MB DOC)
###end p 71
###begin p 72
Click here for additional data file.
###end p 72
###begin p 73
We would like to thank all volunteers for their contribution to the present work. We thank Peter Rees for the English editing. This work is part of S.P. PhD thesis program at Santiago de Compostela University.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
Congenital adrenal hyperplasia.
###end article-title 75
###begin article-title 76
Extensive clinical experience: nonclassical 21-hydroxylase deficiency.
###end article-title 76
###begin article-title 77
Congenital adrenal hyperplasia and P450 oxidoreductase deficiency.
###end article-title 77
###begin article-title 78
Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population.
###end article-title 78
###begin article-title 79
Effect of newborn screening for congenital adrenal hyperplasia.
###end article-title 79
###begin article-title 80
High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland.
###end article-title 80
###begin article-title 81
Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden.
###end article-title 81
###begin article-title 82
Neonatal screening for congenital adrenal hyperplasia.
###end article-title 82
###begin article-title 83
Prevalence of nonclassical steroid 21-hydroxylase deficiency based on a morning salivary 17-hydroxyprogesterone screening test: a small sample study.
###end article-title 83
###begin article-title 84
Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.
###end article-title 84
###begin article-title 85
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Three novel CYP21A2 mutations and their protein modelling in patients with classical 21-hydroxylase deficiency from northeastern Iran.
###end article-title 85
###begin article-title 86
Functional studies of two novel and two rare mutations in the 21-hydroxylase gene.
###end article-title 86
###begin article-title 87
Predisposition for de novo gene aberrations in the offspring of mothers with a duplicated CYP21A2 gene.
###end article-title 87
###begin article-title 88
###xml 32 40 <span type="species:ncbi:9606">patients</span>
CYP21A2 mutations in Portuguese patients with congenital adrenal hyperplasia: identification of two novel mutations and characterization of four different partial gene conversions.
###end article-title 88
###begin article-title 89
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Four novel missense mutations in the CYP21A2 gene detected in Russian patients suffering from the classical form of congenital adrenal hyperplasia: identification, functional characterization, and structural analysis.
###end article-title 89
###begin article-title 90
###xml 88 95 <span type="species:ncbi:9606">patient</span>
A novel frameshift mutation (141delT) in exon 1 of the 21-hydroxylase gene (CYP21) in a patient with the salt wasting form of congenital adrenal hyperplasia. Mutation in brief no. 255. Online.
###end article-title 90
###begin article-title 91
Three novel point mutations of the CYP21 gene detected in classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
###end article-title 91
###begin article-title 92
###xml 81 89 <span type="species:ncbi:9606">patients</span>
High variability in CYP21A2 mutated alleles in Spanish 21-hydroxylase deficiency patients, six novel mutations and a founder effect.
###end article-title 92
###begin article-title 93
Characterization of novel missense mutations in CYP21 causing congenital adrenal hyperplasia.
###end article-title 93
###begin article-title 94
###xml 36 44 <span type="species:ncbi:9606">patients</span>
CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations.
###end article-title 94
###begin article-title 95
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
###end article-title 95
###begin article-title 96
###xml 26 31 <span type="species:ncbi:9606">human</span>
Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations.
###end article-title 96
###begin article-title 97
###xml 16 21 <span type="species:ncbi:9606">human</span>
Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease.
###end article-title 97
###begin article-title 98
Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes.
###end article-title 98
###begin article-title 99
Extended MHC haplotypes and CYP21/C4 gene organisation in Irish 21-hydroxylase deficiency families.
###end article-title 99
###begin article-title 100
Characterization of mutations on the rare duplicated C4/CYP21 haplotype in steroid 21-hydroxylase deficiency.
###end article-title 100
###begin article-title 101
Haplotypes of the steroid 21-hydroxylase gene region encoding mild steroid 21-hydroxylase deficiency.
###end article-title 101
###begin article-title 102
Cribado neonatal de la hiperplasia suprarrenal congenita. Aplicabilidad en Galicia. Axencia de Avaliacion de Tecnoloxias Sanitarias de Galicia avalia-t.
###end article-title 102
###begin article-title 103
Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.
###end article-title 103
###begin article-title 104
PCR-based detection of the CYP21 deletion and TNXA/TNXB hybrid in the RCCX module.
###end article-title 104
###begin article-title 105
###xml 115 123 <span type="species:ncbi:9606">patients</span>
Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.
###end article-title 105
###begin article-title 106
Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation.
###end article-title 106
###begin article-title 107
Genotype-phenotype analysis in late onset 21-hydroxylase deficiency in comparison to the classical forms.
###end article-title 107
###begin article-title 108
CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region.
###end article-title 108
###begin article-title 109
###xml 37 42 <span type="species:ncbi:9606">women</span>
Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
###end article-title 109
###begin article-title 110
###xml 73 78 <span type="species:ncbi:9606">human</span>
Characterization of single-nucleotide polymorphisms in coding regions of human genes.
###end article-title 110
###begin article-title 111
A simple and robust quantitative PCR assay to determine CYP21A2 gene dose in the diagnosis of 21-hydroxylase deficiency.
###end article-title 111
###begin p 112
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 112
###begin p 113
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The authors have no support or funding to report.
###end p 113

